DelSiTech focuses on the development of added value products, based on our drug delivery long-acting formulation platform, across our core therapeutic areas of pain and metabolic disease.
- In the metabolic disease space, the burdens of chronic care on patients with cumbersome dosing regimens are pronounced and challenging for treatment adherence. We are diligently developing solutions with the potential to be best in class and significantly reduce annual administrations through our focus on ultra-long-acting formulations.
- For pain treatment, we believe that new options would be essential for the patients’ benefit. DelSiTech is committed to developing a non-opioid-based, long-acting pain relief solution that aims to reduce the risk of dependence and support pain management during recovery.
In House Programs
| Indication | Product candidate | Research | Pharmaceutical development | Preclinical | Clinical |
|---|
DST-101: Undisclosed ultra long-acting product candidate targeting metabolic disease.
DST-102: Undisclosed ultra long-acting product candidate targeting metabolic disease.
DST-201: Undisclosed long-acting small molecule targeting pain.
DST-2105: A first-in-class long-acting artificial tear candidate. Phase 1 clinical studies have demonstrated the tolerability and usability of the Silica Eye Drop formulation.